Disease Awareness Initiative Launched for Familial Chylomicronemia Syndrome (FCS)

FCS is rare genetic condition that causes severe hypertriglyceridemia and increases the risk of pancreatitis. Rare Disease Communications has created a new web site to educate physicians about FCS and build awareness about its signs and symptoms.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend

Rare Disease Communications publishes the Rare Disease Report

Early recognition is important for treatment of FCS. Children with unexplained high levels of triglycerides, skins rashes, or creamy blood samples should be tested.

Plainsboro, NJ (PRWEB) May 14, 2014

Rare Disease Communications (publisher of Rare Disease Report) has launched a disease awareness initiative to educate U.S. physicians about a rare condition called Familial Chylomicronemia Syndrome (FCS).

The Web site, http://fcs.raredr.com/, is designed to increase FCS awareness among healthcare professionals (HCPs), to educate them on the early signs and symptoms of FCS, and to stress the importance of patients adhering to a strict low-fat diet. Rare Disease Communications developed content for the site.

The site includes 11 videos from a panel of FCS experts, including Daniel Rader, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia; Ira Goldberg, MD, Division of Endocrinology, Diabetes, & Metabolism, NYU Langone Medical Center, New York City; and Wahida Karmally, RD, Institute of Human Nutrition, Columbia University, New York City.

FCS is a very rare hereditary condition in which those affected lack a properly functioning, lipoprotein lipase (LPL), an enzyme that clears triglycerides from plasma. The disruption of the enzyme activity leads to very high concentrations of triglycerides, and particularly, chylomicrons in the blood plasma (chylomicronemia).

FCS is also referred to familial LPL deficiency (LPLD), or hyperlipoproteinemia Type 1. In the new FCS Disease Awareness Initiative, clinicians can learn more about:

  • Genetics, prevalence, and natural history of FCS
  • Clinical signs and symptoms of FCS
  • Treatment options available to lower the risk of pancreatitis
  • Resources available to clinicians treating patients with FCS, including information about patient registries, references to over 30 peer-reviewed articles, and a video library.

Early recognition is important for this very rare condition. Children with unexplained high levels of triglycerides, skin rashes (xanthoma), or creamy blood samples (due to high levels of chylomicrons) should be tested for FCS. An FCS registry is also available to better understand the natural history of this condition.

"We are delighted to announce the launch of the FCS Disease Awareness Initiative,” said Peter Ciszewski, President of Rare Disease Communications, Plainsboro, N.J. “Hopefully, this initiative will raise awareness of this silent disease and bring attention to the patient registry that can help us better understand the natural history of this disease.”

“The mission of Rare Disease Report is to raise awareness of orphan conditions so that patients will be diagnosed and treated more efficiently. This website fulfills that mission,” said James Radke, Vice President of Editorial at Rare Disease Communications, adding, “The website educates endocrinologists, GPs, lipidologists, and others about FCS so that when they see a patient with unexplained pancreatitis or a creamy blood sample, they will be better prepared to suspect FCS and run the proper diagnostic tests.“

“Web sites likes this one are what Rare Disease Communications does best. We can create the content and make sure it gets to its intended audience using our strong social media presence,” Ciszewski said.

It is estimated that 1 in 1 million people are born with FCS. Currently, the standard of care for FCS patients is a very low fat diet (≤ 15% by calories), in which patients consume less than 20-25 grams of fat per day. However, most patients find it very difficult to adhere to such a diet. Patients should also avoid substances known to increase the level of triglycerides in the blood, such as alcohol, diuretics, systemic steroids, and estrogens.

About Rare Disease Communications

Rare Disease Report (http://www.raredr.com) is published by Rare Disease Communications (RDC) LLC, a full service health care agency dedicated to raising awareness of orphan conditions so that patients will be diagnosed and treated more efficiently. RDC is owned in part by MJH & Associates Inc, a healthcare publishing company that reaches nearly every sector of healthcare professionals, providing resources and information to physicians, pharmacists, managed care professionals, and many others. MJH & Associates combines the power of an established network of publications and websites with the customer service focus and customization capabilities of a boutique firm.

CONTACT:     
Peter Ciszewski
pciszewski (at) raredr (dot) com
(914) 413-7174

Intended for U.S. media only
SOURCE: Rare Disease Communications


Contact

  • Peter Csizewski, President
    Rare Disease Communications
    +1 914-413-4174
    Email